Access cutting-edge relapsed/refractory multiple myeloma (rrmm) treatment through this phase 4 clinical trial at a research site in Baton Rouge. Study-provided care at no cost to qualified participants.
Quick Self-Assessment
See if you qualify for this Baton Rouge location
Preparing your pre-screening questions…
Access relapsed/refractory multiple myeloma (rrmm) specialists at no cost
This study follows strict safety protocols and ethical guidelines
All study-related relapsed/refractory multiple myeloma (rrmm) treatment provided free
Check if you qualify for this relapsed/refractory multiple myeloma (rrmm) clinical trial in Baton Rouge, LA
No-Cost Study Care
Local to Baton Rouge
Convenient for LA residents
Cutting-Edge Treatment
Access to innovative therapies
Expert Medical Care
Close monitoring by specialists
Possible Compensation*
For time and travel
*Compensation varies by study. Confirm details with coordinator.
This study is researching whether the use of tocilizumab before the first dose of linvoseltamab will decrease the risk of Cytokine Release Syndrome (CRS) in participants who have Relapsed or Refractory Multiple Myeloma (RRMM) who have already been treated with at least four lines of treatment for their multiple myeloma, including medicines called a proteasome inhibitor, an immunomodulatory drug, and an anti-Cluster of Differentiation (CD) 38 antibody. The aim of the study is to see how safe, tolerable and effective linvoseltamab is when given after tocilizumab. The study is looking at several other research questions, including: * What side effects may happen from taking tocilizumab before the first dose of linvoseltamab * Whether tocilizumab has an impact on CRS, including whether participants require hospital care and, if so, how many hospital visits occur and how long they last * How frequently other medications (for example, corticosteroids or additional doses of tocilizumab) are used to support participants' care if needed
Sponsor: Regeneron Pharmaceuticals
Yes, this clinical trial (NCT07609940) has an active research site in Baton Rouge, LA that is currently enrolling participants.
Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.
Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.
Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.
If you're searching for relapsed/refractory multiple myeloma (rrmm) treatment options in Baton Rouge, LA, this clinical trial (NCT07609940) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our Baton Rouge research site is actively enrolling participants for this phase 4 clinical trial. You'll receive care from experienced relapsed/refractory multiple myeloma (rrmm) specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.
Looking for more options? Browse all relapsed/refractory multiple myeloma (rrmm) clinical trials near you to find additional studies recruiting in your area.
See all multiple myeloma clinical trials recruiting in Baton Rouge — not just this study.
Browse Multiple Myeloma Trials in Baton Rouge →